Who are we?
Who we are
Unipharm was founded in 1975 in Israel and since its early days was a dominant player in the pharmaceutical arena in Israel.
What we do
We create value in the full pharmaceutical value chain from developing to manufacturing and successfully marketing generic pharmaceuticals. We take pride in doing this in an innovative, responsible and cost-efficient way.
What we offer?
We offer product portfolio consisting of a broad range of high quality generics for all major therapeutic areas. It is part of our long-term strategy to expand the product portfolio of off-patent blockbusters while at the same time offering a broader range of niche products within more narrow disease areas.
Unipharm’s products are developed in the CTD dossier format and produced in a manufacturing facility certified in compliance with Good Manufacturing Practices (GMP), which is recognized by the European Union (EU).
Our added value
Unipharm is involved in intellectual activities.
In the current pharmaceutical-IP environment where major pharmaceutical companies are protecting their product with multiple patents, Unipharm has the capabilities of accurately evaluating a product’s patent protection suit and to act accordingly: either stay off the market until the patents expire, to circumvent the still valid patents or to try to invalidate the patent and launch a generic version as soon as legally possible.
Drugs Disributed by Unipharm Trading Ltd, Israel
Atypical Antipsychotic. Aripiprazole 5, 10, 15, 30 mg. TABS: 28 x 5 mg, 10 mg, 15 mg, 30
Take whole w/out meals. Schizophren:
Adult >18 yrs: 10-15 mg dly. Maint. 15
mg dly, max. 30 mg dly. Adolescents
(15 yrs and older): recommend. dose
10 mg dly. Max. dly dose: 30 mg.
Mania: Adult >18 yrs: 15 mg daily, incr.
if necess. to 30 mg dly. Not to exceed
recomm. dose. Irritability
Assoc. with Autistic Dis. (6-17 yrs):
initiate at 2.5 mg/d, dose range 5 – 15
mg dly. See lit.
Tmt. of schizophrenia, tmt. of mod.- severe
manic epis. in Bipolar I disord., prevent. of
a new manic epis. in pts who experienced
predomin. manic epis. whose manic
epis. respond. to aripiprazole tmt. Use as
an adjunct. ther. to antidepress. for tmt. of
major depress. dis. (MDD). Efficacy was
establ. in two 6-week trials in adults with
MDD who had an inadeq. resp. to
antidepr. ther. during the curr. epis. Tmt. of
irritability assoc. with autistic dis. Efficacy
was establ. in two 8-week trials in ped. pts
(aged 6 - 17 yrs) with irritab. assoc. with
autistic dis. (incl. sympt. of aggress.
towards others, delib. self-inj., temper
tantrums, quickly chang. moods).
5-α Reductase Inhibitor. Dutasteride 0.5 mg. SOFT CAPS.: 30. 1 cap.×1/d.
Tmt. of moder. - severe sympt. of BPH. To reduce the risk of acute urin. retent. and surgery in pts. with moder.-severe sympt. of BPH.
C/I: Hypersens. to the active ingred./other 5-α-reductase inhib., soya, peanuts. Severe liver dis. Use in women, child. or adolesc.
Selective Norepinephrine Reuptake Inhibitor. Atomoxetine (as HCl) 25, 40, 60 mg. F.C. TABS.: 28×25, 40, 60mg. Paed. pts. up to 70 kg bdy. wt.: Initial. at a total dly dose of approx. 0.5 mg/kg. The initial dose should be maintain. for a min. of 7 d. prior to upward dose titrat. accord. to clinical response and tolerab. The recommended mainten. dose is approx. 1.2 mg/kg/d. (depend. on the pt’s. wt. and available dosage strengths of atomoxetine).
Dosing of paed. pts. over 70 kg bdy. wt. and Adult.: The Drug should be initiated at a total daily dose of 40 mg. The initial dose should be maintain. for a min. of 7 d. prior to upward dose titrat. accord. to clinical response and tolerab.. The recomm. mainten. dose is 80mg. The max. recom. total dly. dose is 100 mg.
Indicated for the tmt. of ADHD in child. of 6 yrs. and older, in adolesc. & in adult. as part of a comprehensive tmt. programme. Tmt. must be initiated by a specialist in the tmt. of ADHD, such as a paediatrician, child/adolesc. psychiatrist, or psychiatrist. Diagnosis should be made accord. to current DSM criteria or the guidelines in ICD. In adult., the presence of sympt. of ADHD that were pre-exist. in childhood should be confirmed. Third-party corroboration is desirable and the drug should not be initiated when the verification of childhood ADHD sympt. is uncertain. Diagnosis cannot be made solely on the presence of one or more sympt. of ADHD. Based on clinical judgment, pts. should have ADHD of at least moder. severity as indicated by at least moderate function. impair. in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
C/I: Hypersens. Comb. with MAOI. Atomoxetine should not be used within a min. of 14 d. after discont. ther. with MAOI. Tmt. with MAOI should not be init. within 14 d. after discont. atomoxetine.
Pts. with narrow-ang. glauc.
Pts. with pheochromocytom.
Pts. with severe card./vascular disord., hypertens., tachycard.
Angiotensin II Antagonist, Diuretics. Candesartan Cilexetil 16 mg, Hydrochlorothiazide 12.5 mg. TABS: 28. 1 tab dly. See lit.
Essent. HTN, where monother. with
candesartan cilexetil or HCTZ is not
C/I: Hypersens. to ingredients/
sulfonamide derived drugs, pregn., lact.,
severe ren. impair., severe hepat. impair./
cholestas., hypokalem., hypocalcem.,
gout, tmt. with aliskiren in diabetic pts.
or pts. with impair. renal func.